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AbstTPCt 
Two abundant proteins of 140 and 134 amino acids were puritied and sequenced from human brain. They were identfied through their reactivity 
on immunoblots with a partially characterised monoclonal antibody that recognises tau protein in a phosphorylation-dependent manner. The 140 
amino acid protein is identical with the precursor of the non-M component of Alxheimer’s disease amyloid which in turn is highly homologous to 
synuclein from Torpedo electroplaques and rat brain. The 134 amino acid protein is the human homologue of bovine phosphoneuroprotein 14, it 
is 61% identical in sequence to the 140 amino acid protein, The previously unrecognised homology between these two proteins defines a family of 
human brain synucleins. We refer to the 140 and 134 amino acid proteins as a-synuclein and /I-synuclein, respectively. Both synucleins are expressed 
predominantly in brain, where they are concentrated in presynaptic nerve terminals. 
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1. Intruduction 
Abundant senile plaques and neurofibrillary lesions 
constitute the major neuropathological characteristics of 
Alzheimer’s disease. The paired helical filament (PHF) 
is the major fibrous constituent of the neurofibrillary 
lesions (neurofibrillary tangles, neuropil threads and se- 
nile plaque net&es). It is made of microtubule-associ- 
ated protein tau in a hyperphosphorylated state (for 
review see [l]). Consequently, there is great interest in 
identifying the sites in tau that are hyperphosphorylated 
in Alzheimer’s disease brain. Several phosphorylation- 
dependent anti-tau antibodies have been produced and 
used to identify specific amino acids that are 
phosphorylated in PHF-tau [2-71. During immunoblot 
studies with the partially characterised monoclonal anti- 
body 11.57 [S] we noticed that, besides recognising PHF- 
tau and fetal tau in a phosphorylation-dependent man- 
ner, it also strongly labels two protein bands from a 
cytosolic extract prepared from adult brain, each with an 
apparent molecular mass of approximately 19 kDa. Pep- 
tide sequencing showed that these bands contain two 
related proteins and molecular cloning demonstrated 
that they are 134 and 140 amino acids in length. The 140 
amino acid protein is identical with the recently de- 
scribed precursor of the non-@ component of Alz- 
heimer’s disease amyloid (NACP) [9]; it probably repre- 
sents a human synuclein, as it is highly homologous to 
synuclein from Torpedo electroplaques and rat brain 
[lO,l 11. The 134 amino acid protein from human brain 
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Abbreviations: PHF, paired helical 6lame.m; NACP, non-@ component 
of Alzheimer’s disease precursor; PNPl4, phosphoneuroprotein 14. 
is highly homologous to bovine phosphoneuroprotein 14 
(PNP14) [12]. 
The previously unrecognised homology between these 
proteins establishes the existence of a family of human 
brain synucleins. We refer to the 140 and 134 amino acid 
proteins as a-synuclein and /I-synuclein, respectively. 
2. Materials and methods 
2.1. Synuclein pkfication 
Human synucleins were purified using cerebral cortex from control 
brain and Alxheimer’s disease brain. The mean post-mortem time was 
approximately 3 h and the tissues were kept at -70°C until use. Brain 
tissue (wt./vol. 1: 2) was homogenised in 50 mM Tris-HCl, pH 7.0, 1 
mM EDTA, 0.1 mM DTT, 0.1 mM phenylmethylsulphonyl fluoride 
(PMSF) using a Polytron (setting 7 for 30 s). Following a 20 min 
centrifugation at 40,000 x g the supematant was brought to 0.5 M NaCl 
and heated in a boiling water-bath for 10 min. Following a further 
centrifugation the supematant was dialysed against 50 mM Tris-HCl, 
pH 7.4,O. 1 mM DTT, 0.1 mM PMSF. It was then applied to a Mono-Q 
HR5/5 column (flow-rate 1 ml/mm) equilibrated in the same buffer. 
a-Synuclein eluted at 195 mM NaCl and!-synuclein at 240 mM NaCI. 
Final purification was achieved by reverse-phase HPLC. The fraction- 
ated synucleins from the Mono-Q column were applied directly to an 
Aquapore RP-300 column (flow-rate 0.5 ml/min) that had been equili- 
brated in 0.1% TFA and were eluted with a linear gradient of &80% 
acetonitrile + 0.04% TFA. 
2.2. Protein analysis 
Amino acid sequencing of protein fragments that had been electro- 
phoretically transferred to a polyvinylidene difluoride (PVDF) mem- 
brane or of peptides that had been fractionated by reverse-phase HPLC 
was carried out using an ABI gas phase sequencer. A VG Bio-Q triple 
quadruple instrument with electrospray ionisation was used to obtain 
mass spectrometry data. 
Polyclonal antibodies (antisera PER2 and PER3) were raised against 
the synthetic peptide MPVDPDNEAYEMPSEE from a-synuclein (res- 
idues 116131, antiserum PERZ) and the peptide EVAQEAAEEPLIE- 
PL from p-synuclein (residues 99111, antiserum PER3). Each peptide 
(500 pug), coupled to keyhole limpet hemocyanin using glutaraldehyde, 
was mixed 1: 1 with Freund’s complete adjuvant and used to immunise 
white Dutch rabbits. A booster injection was given 2 weeks after the 
primary immunisation using 250 pg of conjugate peptide mixed 1: 1 
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with Freund’s incomplete adjuvant. Another booster injection was 
given after an additional 2 weeks, and the animals were bled 10 days 
later. Immunoblot analysis was carried out with monoclonal antibody 
11.57 and rabbit antisera PER2 (diluted 1: 5.000) and PER3 (diluted 
1: 500) and developed using a Vectastain kit (Vector Laboratories, 
Peterborough, UK). SDS-polyacrylamide gradient gels (10-2095) were 
used to monitor protein purification and for immunoblot analysis. 
2.3. PCR, characterisation of cDNA clones and RNA blot analysis 
Degenerate oligonucleotides were based on the partial protein se- 
quences obtained for a-synuclein and /I-synuclein. The sense oligonu- 
cleotide for both svmtcleins was 5’CGAGCTCAYGTNTT 
GAARGGNYT-Y, where Y is C or T, R is A or G and N is A, G, C 
or T. The anti-sense olieonucleotide was S-CGAGCTCCATYCR- 
TANGCYTCRTTRTC-3; for a-synuclein and S-CGAGCTCT- 
CYTCNGCNGCYTCYTGNGC-3’ for /I-synuclein. A Sac1 site was 
present at the 5’ end of each oligonucleotide, to facilitate subcloning. 
PCR was performed using 5 ng of cDNA prepared by reverse transcrip- 
tion of poly(A)+ RNA from adult human brain cerebral cortex. Samples 
were amplified with Taq polymerase (Perkin Elmer) for 30 cycles with 
conditions of denaturing (94”C, 1 min), annealing (SO’C, 1 min) and 
extension (72”C, 2.5 mm), followed by a final 10 min elongation step 
at 72’C. The PCR products of 385 nucleotides (a-synuclein) and 319 
nucleotides f&nuclei@ were digested with SacI, gel purified, sub- 
cloned into Sac1 cut M13mp18 and sequenced. The amino acid se- 
quences deduced from the DNA sequence contained the sequences used 
to design the oligonucleotides, as well as the partial protein sequences. 
The PCR products were radiolabelled by random priming and used as 
probes to screen a hippocampal cDNA library from adult human brain 
in lambda gt10, as described [13]. Positive plaques were purified, the 
DNA cut with EcoRI. subcloned into EcoRI cut M13mu18 and se- 
quenced on both strands using synthetic primers. _ 
For RNA blot analysis the 3 19 nucleotide PCR fragment of B-synu- 
clein was labelled by random priming and used to probe RNA blots 
containing 2 pg poly(A)+ RNA from various human tissues under high 
stringency conditions (multiple tissue Northern blot membranes, 
Clontech, lots 3 x 833 and 41755). Following autoradiography the 
membrane was stripped in boiling water containing 0.1% SDS and 
re-hybridised with a human B-actin probe labelled by random priming. 
Hybridisations and washings were done exactly as described [ 131. The 
/I- synuclein probe did not cross-hybridise with a-synuclein DNA under 
the conditions used. 
2.4. Bacterial expression of a-synuclein and /I-synuclein 
The coding region and part of the 3’ untranslated region of a-synu- 
clein and @ynuclein were amplified by PCR using cDNA from adult 
human cerebral cortex and Taq polymerase (Perkin Elmer). Samples 
were amplnied for 30 cycles (denaturation 94”C, 1 mm; annealing 
50°C, 1 min; extension 72”C, 2.5 min, followed by a tinal 10 min 
elongation step at 72°C). The sense oligonucleotides contained an NdeI 
site in the context of the initiator codon, whereas the anti-sense oligonu- 
cleotides contained a HindIII site. Each oligonucleotide carried a Sac1 
site at the 5’ end, to facilitate subcloning into M13. The sense oligonu- 
cleotides were: 5’-CGAGCTCCATATGGATGTATTCATGAAAG- 
GAC’IT-3’ for a-svnuclein and S-CGAGCTCCATATGGACGTGT- 
TCATGAAGGGCCTG-3’ for B-synuclein. The anti-sense oligonucle- 
otides were: S-CGAGCTCTCAAGCTTGGATGGAACATCTGTC- 
AGCAG-3’ for a-synuclein and 5’-CGAGCTCAAGCTTCGCGCA- 
GACGCTGGATGGGGAG-3’ for /I-synuclein. After amplification 
the PCR products were digested with SacI, subcloned into Sac1 cut 
M13mp18 and sequenced. Following primer extension the double- 
stranded Ml3 DNA was digested with kdeI/ HindIII, the insert band 
subcloned into NdeWZindIII digested uRK172 and the dasmids trans- 
formed into BL21@E3). BacteAa were grown and induced as described 
[ 141. Recombinant proteins were puritied using boiling and the Mono-Q 
column step, as described above for synuclein purification from brain. 
2.5. Immunohistochemistry 
Paraffin-embedded sections (7 p) through the anterior hippocam- 
pus and adjacent entorhinal cortex from the brain of a 68-year-old 
individual who had died without neurological or psychiatric disorders 
were stained with antisera PER2 and PER3, diluted 1:500 and 1:200, 
respectively. Immunostaining was done with the ABC method 1151 
using the Vectastain kit. Sections were counterstained with hematox- 
ylin. Absorption controls were done by pre-incubating each diluted 
antiserum overnight at 4°C with 20 ,ug/ml of the peptide used as the 
immunogen or with 10 PM recombinant a-synuclein or 10 PM b- 
synuclein. 
3. Results 
3.1. PuriJication and sequence determination of 
a-synuclein and jhynuclein 
We have identified two proteins from a cytosolic ex- 
tract of human brain, each with a similar apparent mo- 
lecular mass of approximately 19 kDa, by virtue of their 
reactivity on immunoblots with monoclonal antibody 
11.57 (Fig. 1); 11.57 recognised the upper of the two 
bands more strongly (Fig. 1). Partial purification was 
achieved by taking advantage of the heat stability of the 
proteins and separation by using a Mono-Q column, as 
the isoelectric points of the two proteins are different. 
Complete purification required an additional HPLC 
step. The amino-terminal amino acid of each protein 
appears to be modified and subsequently was unamena- 
ble to Edman degradation, but analysis of fragments 
produced by limited proteolysis gave significant se- 
quence (up to 55 residues/fragment). PCR products ob- 
tained from these sequences were used to isolate cDNA 
clones encoding each protein by screening a cDNA li- 
brary prepared from adult human hippocampus. The 
frequency of hybridisation-positive cDNA clones was 
high (approximately 1 in 1,000 for each probe). Ten 
cDNA clones were subjected to sequence analysis, giving 
protein sequences of 140 and 134 amino acids. 
The nucleotide sequence and deduced amino acid se- 
quence of the 140 amino acid protein were found to be 
homologous to synuclein from Torpedo electroplaques 
and rat brain [lo, 1 l] and identical to the recently de- 
Fig. 1. Immunoblot of boiled supematant from human brain homoge- 
nate with monoclonal antibody 11.57. Lanes: 1, Coomassie brilliant 
blue staining; 2, Immunoblot staining with 11.57. Size is shown to the 
left in it4, x lo-‘. 
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CCGCCGCAGCCGCCGCTCCATCCCCAGCCCCGGCCCCGCATC~~CCGCCA~TG~C 60 
VFMKGLSMAKEGVVAAAEKT 
GTGTTCATGAAGGGCCTGTCCATGGCCAAGGAGGGCGTTGTGGCAGCCGCGGAGAAAACC 120 
KQGVTEAAEKTKEGVLYVGS 
AAGCAGGGGGTCACCGAGGCGGCGGAWGACCAAGGAGGGCGTCCTCTACGTCGGAAGC 180 
K T R EGVVQGVA SVAEKTKEQ 
AAGACCCGAGAAGGTGTGGTACAAGGTGTGGTGTGGCTTCAGTGGCT GAAAAAACCAAGGAACAG 
ASHLGGAVFSGAGNIAAATG 
GCCTCACATCTGGGAGGAGCTGTGTTCTCT~GGGA 
LVKREEFPTDL KPEEVAQEA 
CTGGTGAAGAGGGAGGAATTCCCTACTGATCTGAAGCCAGAGGAAGTGGCCCAGGAAGCT 
A E E P L IEPLMEPEGESYEDP 
GCTGAAGAACCACTGATTGAGCCCCTGATGGAGCC&AAGGGGAGAGTTATGAGGACCCA 
PQEEYQEYEPEA* 
CCCCAGGAGGAATATCAGGAGTATGAGCCAGAGGCGTAGG~CC~G~~GCCCC~CC 
AGCAGCACMTTCTGTCCCTGTCCCTGCCCCGCCCCCCAG 
TCCTTCTCCCCMTCACGAGATCTTCTTCCTTCTGAGGCCTGTG 
TTAGTGTCTGTCCATCTGTCTGTCCTACCCGCCCGCGTCCMCCCC~G~T~CAGG 
GCCAGGGTTGCGGTCGCGGCTGGGAGCCTCGCCTCGCCCCTC~G~TTGCCTCCTCC~TCCAG 
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Fig. 2. Nucleotide and predicted amino acid sequence of human/3-synuclein. Nucleotides are numbered in the 5’ to 3’ direction and the amino acids 
are shown in single-letter code above the nucleotide sequence. The termination codon is marked by an asterisk. 
scribed NACP [9]. The nucleotide sequence and deduced 
amino acid sequence of the 134 amino acid protein are 
shown in Fig. 2. The protein sequence is highly homolo- 
gous to bovine PNP14 [12]. We refer to the 140 and 134 
amino acid proteins as a-synuclein and /Lsynuclein, re- 
spectively. Using amino acid alignment B-synuclein is 
61% identical to a-synuclein (Fig. 3). The homology is 
greater in the amino-terminal half, where both proteins 
are 84% identical over a stretch of 70 amino acids (Fig. 
3). It is only 30% in the carboxy-terminal half, although 
both proteins share an identical carboxy-terminus. The 
amino-terminal region contains five amino acid repeats 
which are KT(or A)KE(or Q)G(or Q)V for a-synuclein 
and K(or M)T(or A)K(or R)E(or Q)G(or Q)V(or A) for 
/Lsynuclein, giving the consensus sequence KTKEGV 
Each protein has a hydrophobic domain at the centre of 
the molecule. The carboxy-terminal region of each pro- 
tein is rich in prolines and acidic residues, while lacking 
basic residues. There are no cysteine or tryptophan resi- 
dues in either sequence. The calculated molecular mass 
is 14,460 for a-synuclein and 14,288 for B-synuclein. By 
mass spectrometry the molecular masses of recombinant 
a-synuclein and j?-synuclein are 14,462 and 14,291, re- 
spectively. The molecular masses of purified a-synuclein 
and B-synuclein are 14,681 and 14,503, respectively. 
However, on SDS-PAGE, both synucleins have an 
apparent molecular mass of 19 kDa, with a-synuclein 
running slightly faster than /&ynuclein (Fig. 4). Recom- 
binant a-synuclein and ,&synuclein show the same gel 
mobilities as their native counterparts (Fig. 4). 
3.2. Tissue distribution of jkynuclein mRNA 
RNA blot analysis was used to determine the distribu- 
tion of B-synuclein mRNA in a variety of adult human 
tissues (Fig. 5). In brain a strong 1.3 kb band was ob- 
served. Weak hybridisation was observed in skeletal 
muscle, with no detectable hybridisation in heart, pla- 
centa, lung, liver, kidney and pancreas (Fig. 5). No pos- 
itive signal was detected using poly(A)+ RNA from 
human spleen, thymus, prostate gland, testis, ovary, 
small intestine, colon and leucocytes (data not shown). 
3.3. Immunohistochemical localisation of a-synuclein and 
j&synuclein in human brain 
The specificities of antisera PER2 and PER3 were es- 
tablished on immunoblots using native and recombinant 
a-synuclein and /Lsynuclein (Fig. 4). PER2 recognised 
a-synuclein, but not p-synuclein. Conversely, PER3 rec- 
ognised /3-synuclein, while failing to recognise a-synu- 
a Syn 
P Syn 
a Syn 
P Syn 
a Syn 
P Syn 
a Syn 
P Syn 
TGVTAVAQK 
G________ 
Fig. 3. Sequence comparison of human a-synuclein and j%synuclein. 
Amino acids were aligned and two gaps were introduced to maximize 
the homology. Amino acid identities between a-synuclein (a Syn) and 
fi-synuclein (~3 Syn) are indicated by black bars. 
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Fig. 4. Specificity of antisera directed against a-synuclein (antiserum 
PER2) andSsynuclein (antiserum PER3). (A) Coomassie brilliant blue 
staining. (B) Immunoblot staining with PER2. (C) Immunoblot stain- 
ing with PER3. Lanes: 1, native a-synuclein; 2, recombinant a-synu- 
clein; 3, native /I-synuclein; 4, recombinant /I-synuclein. Size is shown 
to the left in M, x lo-‘. 
clein. These antisera were then used to study the distribu- 
tion of a-synuclein and B-synuclein in human entorhinal 
cortex and hippocampus (Fig. 6). In entorhinal cortex 
both PER2 and PER3 gave strong labelling of grey mat- 
ter, where staining was found throughout the neuropil. 
PER2 staining was granular and concentrated around 
nerve cell bodies, outlining the shape of the latter (Fig. 
6A). PER3 staining was more fibrous and nerve cell 
bodies were outlined less clearly (Fig. 6D). This indicates 
the predominant localisation of a-synuclein and /3-synu- 
clein in nerve terminals. In layer CA3 of the hippocam- 
pus both antibodies also strongly labelled nerve termi- 
nals, with slightly different distributions (Fig. 6C,F). 
Both antibodies stained stratum oriens, stratum pyrami- 
dale and stratum radiatum (as described in [16]). How- 
ever, PER2 staining was strongest in stratum oriens (Fig. 
6C), whereas PER3 staining was strongest in stratum 
radiatum (Fig. 6F). PER2 staining was completely abol- 
ished following incubation of the diluted antibody with 
2Opg/ml of the peptide used as the immunogen (Fig. 6B). 
PER3 staining was completely abolished following incu- 
bation of the diluted antibody with 20 @ml of the pep- 
tide used as the immunogen (Fig. 6E). The staining was 
specific for each synuclein, since 10 ,uM recombinant 
a-synuclein, but not 10 ,uM recombinant /I-synuclein, 
completely abolished PER2 staining. Similarly, 10 PM 
/Lsynuclein, but not 10 ,uM a-synuclein, completely abol- 
ished PER3 staining (data not shown). 
4. Discussion 
We have purified two heat-stable proteins from human 
brain, each with an apparent molecular mass of 19 kDa, 
by virtue of their reactivity on immunoblots with 
11.57 [8], a partially characterised monoclonal antibody 
which recognises tau protein in a phosphorylation-de- 
pendent manner. Protein sequencing and molecular clon- 
ing showed that the two proteins are 140 and 134 amino 
acids in length. The 140 amino acid protein is identical 
with the recently described NACP [9], which in turn is 
homologous to synuclein from Torpedo electroplaques 
and rat brain [ 10,111. The nucleotide and deduced amino 
acid sequence of the 134 amino acid protein indicate that 
it is the human homologue of bovine PNP14 [12], as the 
two proteins differ by only four amino acids, three of 
which are conservative substitutions. The 134 amino acid 
protein (called here /?-synuclein) is 61% identical to the 
140 amino acid protein (called here a-synuclein), thus 
establishing the existence of a family of human brain 
synucleins. It remains to be shown whether other mem- 
bers of this protein family exist. Both proteins are prob- 
ably the products of separate genes, since they show a 
number of nucleotide differences in the regions of amino 
acid identity and since their untranslated regions differ 
in sequence. This is confirmed by the partial characteri- 
sation of genomic clones for a-synuclein and @ynuclein 
(data not shown). Recombinant a-synuclein has a molec- 
ular mass of 14,462, compared to the calculated molecu- 
lar mass of 14,460. By contrast, a-synuclein from human 
brain has a molecular mass of 14,681. Recombinant /3- 
synuclein has a molecular mass of 14,291, with a calcu- 
lated molecular mass of 14,288 and a molecular mass of 
14,503 for the native protein purified from human brain. 
This indicates that both synucleins are modified post- 
translationally. It has been suggested that /Lsynuclein is 
a phosphoprotein [12,17]. Future experiments will com- 
bine mass spectrometry with peptide sequencing to iden- 
12345678 
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Fig. 5. RNA blot analysis of poly(A)+ RNA from human tissues, with 
32P-labelled /I-synuclein DNA (A) or human B-actin DNA (B) used as 
a probe. Lanes: 1, heart; 2, brain; 3, placenta; 4, lung; 5, liver; 6, skeletal 
muscle; 7, kidney; 8, pancreas. Each lane contained approximately 2 pg 
poly(A)+ RNA. The blot was re-hybridised with the actin probe after 
de-hybridisation of the/Y-synuclein probe. The autoradiographic expo- 
sure times were 18 h in A and 6 h in B. 
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Fig. 6. Immunohistochemical localisation of a-synuclein (A-C) and 
j?-synuclein (D-E) in human brain using antisera PER2 and PER3. 
(A,D) Bright-field photomicrographs of entorhinal cortex stained with 
PER2 (A) or PER3 (D). Absorption controls with PER2 and PER3 are 
shown in (B) and (E), respectively. (C,F) Dark-field photomicrographs 
of layer CA3 of the hippocampus stained with PER2 (C) or PER3 (F). 
Scale bar in (A) (for A,B,D,E), 60 pm; scale bar in (C) (for C,F), 
180 pm. 
tify these modifications. On SDS-PAGE, both native 
and recombinant synucleins run with an apparent molec- 
ular mass of 19 kDa, with cc-synuclein running slightly 
faster than @ynuclein. This higher apparent molecular 
mass is thus not due to post-translational modifications, 
but may be caused by the negatively charged carboxy- 
termini of both proteins. 
The homology between a-synuclein and j?-synuclein is 
greater in the amino-terminal half, suggesting that this 
region may serve a function shared by the two proteins, 
while the carboxy-terminal half is more divergent, sug- 
gesting different functions. The amino-terminal half of 
each synuclein contains five repeats with the consensus 
sequence KTKEGV. Towards the carboxy-terminus 
each protein contains a number of negatively charged 
residues. Although the function of these sequences is 
unknown it is interesting to note that clusters of basic 
and acidic amino acids frequently mediate binding be- 
tween structural proteins. For instance, the microtubule- 
associated protein MAPlA binds to tubulin through an 
overall negatively charged region, but with a number of 
clusters of acidic and basic amino acids [18]. Similarly, 
the microtubule-associated protein MAPlB binds to tu- 
bulin through KKE repeats [19], villin binds to actin 
through a KKEK motif [20] and actin depolymerisation 
factor, cofilin and tropomyosin carry the DATKKK 
motif [21]. The availability of recombinant synucleins 
allows investigation of possible interactions with struc- 
tural proteins. 
The tissue distribution of human /I-synuclein mRNA 
indicates that it is expressed at high levels in brain, with 
only low levels in skeletal muscle and no detectable hybrid- 
isation in the other tissues investigated. Thus, the ex- 
pression of j.Lsynuclein is largely confined to the nervous 
system. A similar distribution has been found in rat and 
bovine tissues [12,22]. Previous work has shown that 
a-synuclein mRNA is expressed at high levels in human 
brain [9]. However, significant hybridisation was also 
observed in placenta, lung and kidney, indicating that it 
has a less restricted tissue distribution than B-synuclein. 
The cellular localisation of a-synuclein and @ynu- 
clein in human brain was investigated by immunohisto- 
chemistry using antisera specific for each protein. In the 
entorhinal cortex specific staining was concentrated in 
grey matter, where nerve terminals were strongly labelled 
with each antibody, consistent with the presence of a- 
synuclein and /I-synuclein in presynaptic nerve terminals. 
Nerve terminal staining was also observed in layer CA3 
of the hippocampus, where cr-synuclein staining was 
strongest in the stratum oriens and /I-synuclein staining 
in the stratum radiatum. This suggests that there may be 
differences in localisation between the two proteins. Fu- 
ture studies will investigate the detailed distribution of 
each protein. Immunohistochemical studies on rat and 
bovine brain have also shown presynaptic nerve terminal 
staining using antisera raised against sequences from CI- 
synuclein and /?-synuclein [11,17,23]. However, the ho- 
mology between the two synucleins raises questions re- 
garding the specificity of these antisera. We demonstrate 
unambigously that both cz-synuclein and j?-synuclein are 
present in nerve terminals. This localisation is similar to 
that of a number of proteins involved in the events medi- 
ating exocytosis of synaptic vesicles following nerve 
stimulation (for review, see [24]). The abundance of a- 
synuclein and j?-synuclein and their restricted tissue dis- 
tributions suggest a specific role in these events. 
Recently, it was shown that a fragment of a-synuclein 
is a component of at least some of the /VA4 amyloid 
deposits of Alzheimer’s disease [9]. This has led the au- 
thors to propose that in Alzheimer’s disease a-synuclein 
is proteolysed, with its hydrophobic portion becoming 
attached to amyloid fibrils, where it could influence the 
aggregation state of /I/A4 amyloid. The present demon- 
stration of the existence of two different human brain 
synucleins makes it mandatory to examine the distribu- 
tion of a-synuclein and /I-synuclein in Alzheimer’s 
disease brain using specific antibodies directed against 
different parts of each molecule. This could have impli- 
cations for an understanding of the pathogenesis of Alz- 
heimer’s disease. 
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